Neonatal Cardiac Rhabdomyoma: A Single-Center Experience

Abstract

Aim Cardiac rhabdomyoma, known as the most common benign cardiac tumor in childhood, is strongly associated with tuberous sclerosis complex. This study aims to present our single-center experience regarding clinical observations, diagnostic approaches, and treatment modalities for cardiac rhabdomyoma identified during the neonatal period.

Patients and Methods In this clinical observational study, we retrospectively assessed the outcomes of 12 newborn patients diagnosed with cardiac rhabdomyoma who were followed up in our neonatal intensive care unit over the past 12 years.

Results The mean gestational age of the patients was 38.2±1.6 weeks, with an average birth weight of 3193±314 grams. The mean postnatal age at initial diagnosis was 12.42±15.75 days. Tuberous sclerosis complex was clinically identified in 50% of cases (six patients). Seven infants received everolimus treatment, while three infants underwent clinical monitoring without specific interventions. A significant reduction in cardiac mass size was observed in all surviving patients, leading to their subsequent discharge from the hospital.

Conclusion Cardiac rhabdomyomas often undergo spontaneous regression in early childhood. However, in cases with obstructive lesions or arrhythmias, they may present life-threatening consequences. Timely diagnosis, appropriate clinical management, and monitoring are crucial in optimizing outcomes for neonates with cardiac rhabdomyoma.

Keywords

cardiac rhabdomyoma - tuberous sclerosis complex - neonatal outcomes

Publication History

Received: 06 January 2024

Accepted: 30 April 2024

Article published online:
13 June 2024

• References

• 1 Tzani A, Doulamis IP, Mylonas KS. et al. Cardiac tumors in pediatric patients: A systematic review. World J Pediatr Congenit Heart Surg 2017; 8: 624-632 DOI: 10.1177/2150135117723904.
• 2 Pipitone S, Mongiovì M, Grillo R. et al. Cardiac rhabdomyoma in intrauterine life: clinical features and natural history. A case series and review of published reports. Ital Heart J 2002; 3: 48-52
• 3 Yuan SM. Fetal primary cardiac tumors during perinatal period. Pediatr Neonatol 2017; 58: 205-210 DOI: 10.1016/j.pedneo.2016.07.004.
• 4 Isaacs H. Fetal and neonatal cardiac tumors. Pediatr Cardiol 2004; 25: 252-273 DOI: 10.1007/s00246-003-0590-4.
• 5 Benvenuti LA, Aiello VD, Fukasawa S. et al. Cardiac rhabdomyomas exhibit a fetal pattern of atrial natriuretic peptide immunoreactivity. Exp Mol Pathol 2001; 70: 65-69 DOI: 10.1006/exmp.2000.2331.
• 6 Degueldre SC, Chockalingam P, Mivelaz Y. et al. Considerations for prenatal counselling of patients with cardiac rhabdomyomas based on their cardiac and neurologic outcomes. Cardiol Young 2010; 20: 18-24 DOI: 10.1017/S1047951109992046.
• 7 Gupta A, Narula N, Mahajan R. et al. Sudden death of a young child due to cardiac rhabdomyoma. Pediatr Cardiol 2010; 31: 894-896 DOI: 10.1007/s00246-010-9731-9738.
• 8 Myers KA, Wong KK, Tipple M. et al. Benign cardiac tumours, malignant arrhythmias. Can J Cardiol 2010; 26: e58-e61 DOI: 10.1016/s0828-282x(10)70009-x.
• 9 Miyake CY, Del Nido PJ, Alexander ME. et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol 2011; 58: 1903-1909 DOI: 10.1016/j.jacc.2011.08.005.
• 10 Frudit P, Vitturi BK, Navarro FC. et al. Multiple cardiac rhabdomyomas in tuberous sclerosis complex: case report and review of the literature. Autops Case Rep 2019; 9: e2019125 DOI: 10.4322/acr.2019.125..
• 11 Careddu L, Oppido G, Petridis FD. et al. Primary cardiac tumours in the paediatric population. Multimed Man Cardiothorac Surg 2013; 2013: mmt013 DOI: 10.1093/mmcts/mmt013.
• 12 Portocarrero LKL, Quental KN, Samorano LP. et al. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol 2018; 93: 323-331 DOI: 10.1590/abd1806-4841.20186972.
• 13 Törer B, Çetinkaya B, Arslan A. et al. Cardiac rhabdomyoma associated with tuberosclerosis complex in a newborn. Cukurova Med J 2016; 41: 52-55 DOI: 10.17826/cutf.254611.
• 14 International Tuberous Sclerosis Complex Consensus Group. Northrup H, Aronow ME, Bebin EM. et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123: 50-66 DOI: 10.1016/j.pediatrneurol.2021.07.011.
• 15 Yıldırım S, Aypar E, Aydın B. et al. Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment. Turk J Pediatr 2023; 65: 479-488 DOI: 10.24953/turkjped.2022.922.
• 16 Silva-Sánchez MP, Alvarado-Socarras JL, Castro-Monsalve J. et al. Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas. Am J Med Genet A 2021; 185: 1525-1531 DOI: 10.1002/ajmg.a.62120.
• 17 Franz DN, Belousova E, Sparagana S. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One 2016; 11: e0158476 DOI: 10.1371/journal.pone.0158476.
• 18 Ng KH, Ng SM, Parker A. Annual review of children with tuberous sclerosis. Arch Dis Child Educ Pract Ed 2015; 100: 114-121 DOI: 10.1136/archdischild-2013-304948.
• 19 Chao AS, Chao A, Wang TH. et al. Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis. Ultrasound Obstet Gynecol 2008; 31: 289-295 DOI: 10.1002/uog.5264.
• 20 Bader RS, Chitayat D, Kelly E. et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 2003; 143: 620-624 DOI: 10.1067/S0022-3476(03)00494-3.
• 21 Bornaun H, Oztarhan K, Erener-Ercan T. et al. Regression of cardiac rhabdomyomas in a neonate after everolimus treatment. Case Rep Pediatr 2016; 2016: 8712962 DOI: 10.1155/2016/8712962.
• 22 Hood HW, Dodge-Khatami A, Parnell AS. et al. Biventricular repair in a neonate with obstructive inflow cardiac rhabdomyoma and tuberous sclerosis. World J Pediatr Congenit Heart Surg 2015; 6: 307-310 DOI: 10.1177/2150135114561689.
• 23 Black MD, Kadletz M, Smallhorn JF. et al. Cardiac rhabdomyomas and obstructive left heart disease: histologically but not functionally benign. Ann Thorac Surg 1998; 65: 1388-1390 DOI: 10.1016/s0003-4975(98)00180-5.
• 24 Miyake CY, Del Nido PJ, Alexander ME. et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol 2011; 58: 1903-1909 DOI: 10.1016/j.jacc.2011.08.005.
• 25 Chao AS, Chao A, Wang TH. et al. Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis. Ultrasound Obstet Gynecol 2008; 31: 289-295 DOI: 10.1002/uog.5264..
• 26 Cavalcante CTMB PintoVC, Pompeu RG. et al. Perinatal unusual rhabdomyoma location- case report and systematic reviews of the literature. J Matern Fetal Neonatal Med 2021; 34: 137-151 DOI: 10.1080/14767058.2019.1597044..
• 27 Butany J, Nair V, Naseemuddin A. et al. Cardiac tumors: Diagnosis and management. Lancet Oncol 2005; 6: 219-2813 DOI: 10.1016/S1470-2045(05)70093-0.
• 28 Uzun O, Wilson DG, Vujanic GM. et al. Cardiac tumours in children. Orphanet J Rare Dis 2007; 2: 11 DOI: 10.1186/1750-1172-2-11.
• 29 Mas C, Penny DJ, Menahem S. Pre-excitation syndrome secondary to cardiac rhabdomyomas in tuberous sclerosis. J Paediatr Child Health 2000; 36: 84-86 DOI: 10.1046/j.1440-1754.2000.00443.x.
• 30 Amelia A, Mohd Nizam MB. Perinatal management of cardiac tumors: a case series. Med J Malaysia 2013; 68: 374-375
• 31 Randle SC. Tuberous sclerosis complex: a review. Pediatr Ann 2017; 46: 166-1671 DOI: 10.3928/19382359-20170320-01.
• 32 Dass BB, Scharma J. Cardiac rhabdomyoma and tuberous sclerosis: Prenatal diagnosis and follow-up. Indian J Pediatr 2003; 70: 87-89 DOI: 10.1007/BF02722750.
• 33 Wortmann SB, Reimer A, Creemers JW. et al. Prenatal diagnosis of cerebral lesions in ruberous sclerosis complex (TSC). Case report and review of the literature. Eur J Paediatr Neurol 2008; 12: 123-126 DOI: 10.1016/j.ejpn.2007.06.006.
• 34 Luo C, Ye WR, Shi W. et al. Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet J Rare Dis 2022; 17: 106 DOI: 10.1186/s13023-022-02266-0.
• 35 Sadowski K, Kotulska K, Schwartz RA. et al. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol 2016; 30: 586-594 DOI: 10.1111/jdv.13356.
• 36 DiMario FJ, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am 2015; 62: 633-648 DOI: 10.1016/j.pcl.2015.03.005.
• 37 Ng KH, Ng SM, Parker A. Annual review of children with tuberous sclerosis. Arch Dis Child Educ Pract Ed 2015; 100: 114-121 DOI: 10.1136/archdischild-2013-304948.
• 38 University of Washington. Tuberous Sclerosis Complex. 1999 GeneReviews^® [Internet] https://scholar.google.com.tr/ last updated 9.12.2021
• 39 Roach ES. Applying the lessons of tuberous sclerosis: the 2015 Hower Award Lecture. Pediatr Neurol 2016; 63: 6-22 DOI: 10.1016/j.pediatrneurol.2016.07.003.
• 40 Jacks SK, Witman PM. Tuberous Sclerosis Complex: An Update for Dermatologists. Pediatr Dermatol 2015; 32: 563-570 DOI: 10.1111/pde.12567..
• 41 International Tuberous Sclerosis Complex Consensus Group. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 243-254 DOI: 10.1016/j.pediatrneurol.2013.08.001.
• 42 Erol İ, Savaş T, Şekerci S. et al. Tüberoskleroz kompleksi; Tek merkez deneyimi. Türk Ped Arş 2015; 50: 51-60
• 43 Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14: 733-745 DOI: 10.1016/S1474-4422(15)00069-1.
• 44 Davis PE, Filip-Dhima R, Sideridis G. et al. Presentation and diagnosis of tuberous sclerosis complex in infants. Pediatrics 2017; 140: e20164040 DOI: 10.1542/peds.2016-4040.
• 45 Zhang F, Xie L, He X. et al. Tuber brain proportion determines epilepsy onset in children with tuberous sclerosis complex. Pediatr Neurol 2021; 129: 39-45 DOI: 10.1016/j.pediatrneurol.2021.12.012.
• 46 Ohtsuka Y. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: primary short-term study and extension study. Epilepsy Behav 2018; 78: 134-141 DOI: 10.1016/j.yebeh.2017.09.010.
• 47 Karnak I, Alehan D, Ekinci S. et al. Cardiac rhabdomyoma as an unusual mediastinal mass in a newborn. Pediatr Surg Int 2007; 23: 811-814 DOI: 10.1007/s00383-007-1875-0.
• 48 Franz DN, Agricola K, Mays M. et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol 2015; 78: 929-938 DOI: 10.1002/ana.24523.
• 49 French JA, Lawson JA, Yapici Z. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 2153-2163 DOI: 10.1016/S0140-6736(16)31419-2.
• 50 Koenig MK, Hebert AA, Roberson J. et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D 2012; 12: 121-126 DOI: 10.2165/11634580-000000000-00000.
• 51 Demir HA, Ekici F, Erdem AY. et al. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics 2012; 130: 243-247 DOI: 10.1542/peds.2011-3476.
• 52 Curatolo P, Franz DN, Lawson JA. et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Heal 2018; 2: 495-504 DOI: 10.1016/S2352-. 4642(18)30099-3
• 53 Kotulska K, Chmielewski D, Borkowska J. et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013; 17: 479-485